Peer-reviewed veterinary case report
Radiation with low-dose cisplatin for dog nasal sinus cancer safety
By Nadeau, Marie-Eve et al.Ā·Published in Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology AssociationĀ·2004Ā·University of Illinois Veterinary Teaching Hospital, United StatesĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Cobalt radiation with or without low-dose cisplatin for treatment of canine naso-sinus carcinomas.
- Species:
- dog
Plain-English summary
A group of dogs with nasal and sinus tumors received radiation therapy, with some also getting a low dose of cisplatin, a chemotherapy drug, to see if it would help. Out of 31 dogs, those who received both treatments did not experience more side effects than those who only had radiation. Although some dogs had to stop cisplatin due to kidney issues, none developed long-term kidney disease. Overall, the dogs lived for an average of about 14 months, with a few still alive at the end of the study.
People also search for: dog nasal tumor treatment Ā· cisplatin side effects in dogs Ā· radiation therapy for dog cancer
Abstract
The objective of this study was to determine if low-dose cisplatin could be added safely to radiation therapy for the treatment of naso-sinus carcinomas in dogs. Thirty-one dogs were evaluated; 18 of these dogs received cobalt radiation in combination with low-dose cisplatin while 13 dogs received radiation alone. No difference was observed for acute or late radiation effects. Cisplatin was administered at a dosage of 7.5 mg/m2 20 min prior to every other radiation treatment. An initial dose of 10 mg/m2 was intended but toxicity (primarily azotemia) was unacceptable. Cisplatin was administered as prescribed in 12 of 18 dogs. Cisplatin was discontinued in 2 dogs because of azotemia. In the other 4 dogs cisplatin was not administered as prescribed because the dogs were withdrawn from treatment due to disease progression or radiation effects. There was no long-term renal disease in patients who developed azotemia. The overall median survival was 433 days with 4 (12.9%) dogs still alive at the completion of the study.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15373266/